| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
| ||||||||||||||
| ||||||||||||||
|
|
|
|
||||||||||||
|
||||||||||||||
From the *Department of Anesthesiology, Duke University Medical Centre, Durham, North Carolina; Department of Anesthesiology and Perioperative Care, University of California, San Francisco, Medical Center at Mt. Zion, San Francisco, California; University of Kansas Medical Center, Kansas City, Kansas; Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts; ||Huntington Memorial Hospital, Clinical Management Services, Inc., Pasadena, California; ¶Memorial Hermann Memorial City Hospital, Houston, TX; and #Merck Research Laboratories, Blue Bell, Pennsylvania.
Address correspondence and reprint requests to Tong J. Gan, MD, Department of Anesthesiology, Duke University Medical Centre, Durham, NC 27710. Address e-mail to gan00001{at}mc.duke.edu.
BACKGROUND: Antiemetics currently in use are not totally effective. Neurokinin-1 receptor antagonists are a new class of antiemetic that have shown promise for chemotherapy-induced nausea and vomiting. This is the first study evaluating the efficacy and tolerability of the neurokinin-1 receptor antagonist, aprepitant, for the prevention of postoperative nausea and vomiting.
METHODS: In this multicenter, double-blind trial, we randomly assigned 805 patients receiving general anesthesia for open abdominal surgery to a preoperative dose of aprepitant 40 mg orally, aprepitant 125 mg orally, or ondansetron 4 mg IV. Vomiting, nausea, and use of rescue therapy were assessed over 48 h after surgery. Treatments were compared using logistic regression.
RESULTS: Incidence rates for the primary end point (complete response [no vomiting and no use of rescue] over 0–24 h after surgery, tested for superiority of aprepitant) were not different across groups (45% with aprepitant 40 mg, 43% with aprepitant 125 mg, and 42% with ondansetron). The incidence of no vomiting (0–24 h) was higher with aprepitant 40 mg (90%) and aprepitant 125 mg (95%) versus ondansetron (74%) (P < 0.001 for both comparisons), although between-treatment use of rescue and nausea control was not different. Both aprepitant doses also had higher incidences of no vomiting over 0–48 h (P < 0.001). No statistically significant differences were seen among the side effect profiles of the treatments.
CONCLUSIONS: Aprepitant was superior to ondansetron for prevention of vomiting in the first 24 and 48 h, but no significant differences were observed between aprepitant and ondansetron for nausea control, use of rescue, or complete response.
This article has been cited by other articles:
|
|
 |
|
  V. Chinnappa and F. Chung Post-discharge nausea and vomiting: an overlooked aspect of ambulatory anesthesia?/Nausees et vomissements apres le conge : un aspect neglige de l'anesthesie ambulatoire ? Can J Anesth, September 1, 2008; 55(9): 565 - 571. [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. White, O. Sacan, N. Nuangchamnong, T. Sun, and M. R. Eng The Relationship Between Patient Risk Factors and Early Versus Late Postoperative Emetic Symptoms Anesth. Analg., August 1, 2008; 107(2): 459 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. L. Yang, H. Y. Lai, J. J. Wang, P. K. Wang, T. Y. Chen, C. C. Chu, and Y. Lee The timing of haloperidol administration does not affect its prophylactic antiemetic efficacy: [Le moment choisi pour l'administration d'haloperidol n'affecte pas son efficacite anti-emetique prophylactique] Can J Anesth, May 1, 2008; 55(5): 270 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Carides, T. Reiss, C. Lines, B. McKeon, and P. Diemunsch Comparisons of aprepitant and ondansetron Am. J. Health Syst. Pharm., December 1, 2007; 64(23): 2422 - 2424. [Full Text] [PDF]
|
|
|
|
|
|
M. Cavaretta and J. Noviasky Comparisons of aprepitant and ondansetron Am. J. Health Syst. Pharm., December 1, 2007; 64(23): 2424 - 2426. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Gan, T. A. Meyer, C. C. Apfel, F. Chung, P. J. Davis, A. S. Habib, V. D. Hooper, A. L. Kovac, P. Kranke, P. Myles, et al. Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting Anesth. Analg., December 1, 2007; 105(6): 1615 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. White The Importance of Transparency in Industry-Sponsored Multicenter Clinical Studies Anesth. Analg., December 1, 2007; 105(6): 1861 - 1861. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Gan, C. C. Apfel, A. Kovac, B. K. Philip, N. Singla, H. Minkowitz, A. S. Habib, A. Carides, K. J. Horgan, J. K. Evans, et al. The Importance of Transparency in Industry-Sponsored Multicenter Clinical Studies Anesth. Analg., December 1, 2007; 105(6): 1861 - 1862. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Diemunsch, T. J. Gan, B. K. Philip, M. J. Girao, L. Eberhart, M. G. Irwin, J. Pueyo, J. E. Chelly, A. D. Carides, T. Reiss, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery Br. J. Anaesth., August 1, 2007; 99(2): 202 - 211. [Abstract] [Full Text] [PDF]
|
|
|
